Congratulations to the Apogee Therapeutics team on their latest milestone! This morning, the team announced the first participants have been dosed in the Phase 1 clinical trial of APG990, a novel, half-life extended anti-OX40L monoclonal antibody. We are so proud of their continued efforts to help patients with atopic dermatitis and other inflammatory diseases. Well done Michael Henderson, Carl Dambkowski, and the entire team!
We are excited to announce the first participants have been dosed in the Phase 1 clinical trial of APG990, our novel, half-life extended monoclonal antibody targeting OX40L, initially being developed as a treatment for people living with #atopicdermatitis. CMO Carl Dambkowski shares insight into this milestone below. Learn more in the press release here. https://lnkd.in/ezrSM_8c